Get the Stockscreener App
1.05
2.78%
-0.03
After Hours:
1.05
NanoViricides Inc stock is traded at $1.05, with a volume of 355.71K.
It is down -2.78% in the last 24 hours and down -11.76% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
355.71K
Relative Volume:
1.01
Market Cap:
$22.65M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.50
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-11.02%
1M Performance:
-11.76%
6M Performance:
-38.24%
1Y Performance:
-4.55%
1-Day Range:
$1.04
$1.08
1-Week Range:
$1.04
$1.19
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.05 | 23.29M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Can NanoViricides Inc continue delivering strong returnsQuarterly Growth Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - hattiesburgamerican.com
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference - chronicle-tribune.com
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - hattiesburgamerican.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - hattiesburgamerican.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - naplesnews.com
ETF Watch: Should I hold or sell NanoViricides Inc nowJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Can NanoViricides Inc. continue delivering strong returnsInstitutional Holding Changes & Outstanding Investment Trading - bollywoodhelpline.com
Aug Momentum: Is NanoViricides Inc forming a bullish divergenceTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Support Test: Should I invest in NanoViricides Inc before earningsJuly 2025 PostEarnings & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Jobs Data: How much upside does NanoViricides Inc have2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
NanoViricides Highlights Need for Broad-Spectrum Antivirals During Severe Influenza Season - citybuzz -
NanoViricides highlights need for broad-spectrum antivirals amid severe flu season - Proactive financial news
San Gabriel Valley Tribune - FinancialContent
Options Flow: Will NanoViricides Inc. stock continue dividend increases2025 Winners & Losers & Short-Term Swing Trade Alerts - Bộ Nội Vụ
Market Recap: Can NanoViricides Inc NV3P stock sustain institutional flowsInflation Watch & Stock Portfolio Risk Control - Bộ Nội Vụ
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
Published on: 2026-01-10 19:47:32 - ulpravda.ru
Volume Summary: Will NanoViricides Inc NV3P stock outperform small cap peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - patriotledger.com
Can NanoViricides Inc. stock outperform in 2025 bull marketJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - Улправда
Can NanoViricides Inc. stock hit record highs againPortfolio Update Summary & Expert Curated Trade Setup Alerts - Улправда
Geopolitics Watch: How analysts rate NanoViricides Inc. stock todayInflation Watch & Fast Moving Stock Trade Plans - Улправда
Inflation Data: How SUNE stock reacts to inflationary pressuresJuly 2025 Summary & Verified Technical Trade Signals - moha.gov.vn
Can NanoViricides Inc. stock sustain market leadershipJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда
How risky is NanoViricides Inc. stock nowJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - Улправда
Market Review: Is NanoViricides Inc. stock oversold or undervaluedQuarterly Trade Report & Low Drawdown Trading Strategies - ulpravda.ru
How analysts rate NanoViricides Inc. stock todayQuarterly Profit Report & Weekly Stock Breakout Alerts - Улправда
Can NanoViricides Inc. stock weather global recessionBull Run & Daily Profit Focused Screening - ulpravda.ru
Is NanoViricides Inc stock oversold or undervaluedMarket Growth Review & Reliable Entry Point Trade Alerts - Bộ Nội Vụ
Profit Recap: How risky is NanoViricides Inc stock nowJuly 2025 PreEarnings & Consistent Profit Alerts - Bộ Nội Vụ
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - thespectrum.com
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - coloradoan.com
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Register-Guard
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - The Register-Guard
Hogs Drift in a Quiet Session - Barchart.com
Cotton Faces Pressure into the Close - Barchart.com
Wild Yangtze: Echoes of Life from the River’s Rare Species - Barchart.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
4.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):